Aminolevulinic acid - Biofrontera

Drug Profile

Aminolevulinic acid - Biofrontera

Alternative Names: 5-Aminolevulinic acid - Biofrontera; Ameluz; Aminolevulinic acid hydrochloride - Biofrontera; BF-200 ALA; L01XD04

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ASAT AG
  • Developer Biofrontera AG; Louis Widmer
  • Class Amino acids; Antineoplastics; Keto acids; Levulinic acids; Oxidants; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Actinic keratosis
  • Phase III Basal cell cancer
  • No development reported Condylomata acuminata

Most Recent Events

  • 28 Jul 2017 Biofrontera Bioscience initiates enrolment in a phase III trial for Actinic keratosis in Germany (EudraCT2017-000486-72)
  • 21 Jul 2016 The Committee for Medicinal Products for Human Use adopts a positive opinion recommending an extension to the existing indication of Actinic keratosis for aminolevulinic acid
  • 11 May 2016 Registered for Actinic keratosis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top